The role of intravenous iron in cancer-related anemia.
Oncology (Williston Park, N.Y.)., Jul;20(8 Suppl 6):21-4 (2006)
Blood management in total joint arthroplasty.
Am J. Orthop., Oct;35(10):458-64 (2006)
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
AIDS Res. Hum. Retroviruses., Jan;23(1):1-9 (2007)
Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Drugs., 67(2):175-94 (2007)
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Oncologist., Feb;12(2):231-42 (2007)
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.
Support Care Cancer., Jul;16(7):791-801 (2008)
Parenteral iron therapy in cancer-associated anemia.
Hematology Am Soc Hematol Educ Program., 2010:351-6 (2010)
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
J. Clin. Oncol., Mar;29(9):1125-32 (2011)
Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Support Care Cancer., Sep;20(9):2089-96 (2012)
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Am. J. Hematol., Mar;87(3):308-10 (2012)
Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
Oncology (Williston Park, N.Y.)., Oct;16(10 Suppl 11):9-12 (2002)
Preoperative use of recombinant human erythropoietin before total joint arthroplasty.
J Bone Joint Surg Am., Sep;85-A(9):1795-800 (2003)
The evolving role of epoetin alfa in cancer therapy.
Oncologist., 9(1):97-107 (2004)
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
Arch. Intern. Med., Feb;164(3):262-76 (2004)
Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future.
J. Acquir. Immune Defic. Syndr., Oct;37(2):1221-7 (2004)
Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update.
Expert Opin Pharmacother., Feb;6(2):295-310 (2005)
Experience with epoetin alfa and acquired immunodeficiency syndrome anemia.
Semin. Oncol., Jun;25(3 Suppl 7):64-8 (1998)
Epoetin alfa and high-dose chemotherapy.
Semin. Oncol., Jun;25(3 Suppl 7):54-7 (1998)
A retrospective review of blood transfusions in cancer patients with anemia.
Oncologist., 4(4):318-24 (1999)
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
Ann. Intern. Med., Nov;117(9):739-48 (1992)
Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Semin. Oncol., Apr;21(2 Suppl 3):21-8 (1994)
The management of cancer anemia.
Support Care Cancer., Nov;2(6):403-4 (1994)
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
Cancer J Sci Am., 1(4):252-60 (1995)
Erythropoietin therapy in AIDS.
Prog. Clin. Biol. Res., 338:113-20 (1990)
Changing patterns of care in the management of anemia.
Semin. Oncol., Jun;19(3 Suppl 8):3-7 (1992)
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
Curr Med Res Opin., Jul;22(7):1403-13 (2006)
Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients.
Semin. Hematol., Jan;33(1 Suppl 1):2-5 (1996)
Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Surgery., Oct;128(4):564-71 (2000)
Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma.
Cancer., Nov;86(9):1840-7 (1999)
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
Ann. Oncol., Jul (2012)
Clinical application of recombinant erythropoietin in anemic cancer patients.
Hematol. Oncol. Clin. North Am., Oct;8(5):961-73 (1994)
Protein A immunotherapy in the treatment of cancer: an update.
Semin. Hematol., Apr;26(2 Suppl 1):19-24 (1989)
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
J. Clin. Oncol., Nov;14(11):3026-35 (1996)
Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.
Med. Oncol., Apr;15(1):50-7 (1998)
Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
J. Natl. Cancer Inst., Feb;89(4):301-7 (1997)